Mini-Review
Artemisinin: A Malaria Drug. What Else Could it be Used For?
Enrique Konstat-Korzenny*
Corresponding Author: Enrique Konstat-Korzenny, Av. Mexico s/n. Santiago Yancuitlalpan, Estado de Mexico, Mexico
Received: June 20, 2020; Revised: July 02, 2020; Accepted: August 17, 2020
Citation: Konstat-Korzenny E. (2020) Artemisinin: A Malaria Drug. What Else Could it be Used For? J Blood Transfusions Dis, 3(2): 158-159.
Copyrights: ©2020 Konstat-Korzenny E. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Share :

Artemisinin is the chemical compound obtained from the Artemisia annua plant, a component of Chinese traditional medicine and herbolary. Its use has been described for over 2000 years, mainly for its antipyretic activity. In the 1970s the compound was discovered in China and has since been used to treat Malaria. Recently, studies both in vivo and in vitro have shown that artemisinin is not only capable of treating Malaria, but other diseases. Most of these studies have centered on its antineoplastic activity, while others have study it in other fields of medicine, such as dermatology. Because of its low adverse effect rate, artemisinin and its synthetic derivatives could change the current paradigm of chemotherapy against cancer.

Interestingly, there is only one report of an artemisinin derivative to treat patients infected with the SARS-CoV-2 virus, responsible for the COVID-19 pandemic.

Keywords: Artemisinin, Artesunate, COVID-19, Malaria, Herbolary

REVIEW

Artemisia annua is plant commonly used in Chinese traditional medicine and herbolary. It has been described for over two thousand years, mainly for its antipyretic effects. However, it was not until the 1970s that the active compound, artemisinin, was found by Dr. Youyou Tu while performing research to find alternative treatments for Malaria, because at the time there was an outbreak that proved to be resistant to chloroquine and quinolones, the standard treatment for the disease in the past [1]. She would eventually be awarded the Nobel prize in Medicine or Physiology for those findings in 2015.

Later on, synthetic derivatives such as artesunate, artemether, arteether, dihydroartemisinin among others, were developed and have proved to be more effective against the Plasmodium parasite than the original compound [2]. The artemisinin compound is a sesquiterpene with an endoperoxide group, which is the main source of its cell toxicity capacities.

Artemisinin is only approved for the treatment of Malaria; however, it has also been used to treat other diseases and is now a prospect drug for cancer treatment. The main breakthrough with these findings is not the anticancer capabilities of the compounds, but rather its minimal adverse effect rates [3,4].

Currently approved chemotherapy schemes include specific medications that partake in stopping the cell cycle or inhibiting proteins and enzymes necessary for cell replication. Although effective and powerful, those medications tend to cause severe adverse effects to the patient, many times causing to stop treatment.

The way that artemisinin acts to stop the growth of neoplastic cells is vast and still not clearly defined, however, many mechanisms of action have been shown to be a part of this spectrum and include endoperoxide bridges interacting with heme groups in cancer cells, therefore producing cytotoxic radicals, induction of apoptosis via cyclin dependent kinases (CDK) and procaspases, inhibition of cellular replication pathways, assembling of lysosomes, and have also been proved to inhibit metastasis [5-9].

Studies have reported artemisinin and its compounds as synergistic drugs for currently approved cancer medications, as well as sensitizing agents for multidrug resistant cancer cells [4].

Artemisinin or other derivatives have been widely studied as a possible alternative cancer therapy, but recent evidence has shown that it could also be possibly used for other diseases.

In the field of dermatology, it has been noted as a drug prospect for common pathologies. For example, it has been studied for its ability to modulate scar formation and its beneficial effect on seborrheic keratoses [10,11].

Artesunate was shown to be effective against other parasitic infections such as schistosomiasis and could also be effective against viral pathogens such as Cytomegalovirus, and other members of the Herpesviridae family [12,13]. With this antiviral effect studied, it is noteworthy to mention the possibility of artemisinin and its derivative as a treatment prospect for SARS-CoV-2 virus, which causes the COVID-19 disease, currently a pandemic that has reached all continents and infected over 8 million people as of mid-June 2020 (https://coronavirus.jhu.edu/map.html).

Because of its interaction and inhibition of cell signalling pathways involving NF-kB (Nuclear Factor kappa B) and other interleukins, it is believed that these drugs could be effective and should be considered and studied to treat COVID-19 patients in the setting of a clinical trial [14].

As of mid-June 2020, there is only one article in which artesunate was used to treat COVID-19 patients.

In a study published in April 2020 in the Nanning region of China, artesunate was studied for its possible antiviral effect. The control group of the study consisted of 25 patients and were treated with lopinavir-ritonavir and aerosolized interferon, which they designate as their “standard” treatment, while 18 patients in the experimental group were treated with 60 mg of artesunate twice daily plus the “standard” treatment. At the cut off of 10 days, the experimental group showed a reduced time of symptom improvement, negative SARS-CoV-2 PCR, lung lesion absorption and length of hospital stay, compared with the control group. All data was statistically significant (p < 0.05) [15].

With this brief report in mind, it is quintessential to think of artemisinin and its derivatives as prospects for many diseases. Because of the minimal adverse effect rates, scientists should expand clinical trials both in-vitro and in-vivo to study its benefits and interactions in other morbidities besides Malaria.

1.      Tu Y (2016) Artemisinin-A gift from Traditional Chinese medicine to the world (Nobel Lecture) Angew. Chem Int 55: 10210-10226.

2.      Li Y (2012) Qinghaosu (artemisinin): Chemistry and pharmacology. Acta Pharmacol Sin 33: 1141-1146.

3.      Ribeiro IR, Olliaro PL (1998) Safety of artemisinin and its derivatives: A review of published and unpublished clinical trials. Med Trop (Mars) 58: 50-53.

4.      Konstat-Korzenny E, Ascencio-Aragón JA, Niezen-Lugo S, Vázquez-López R (2018) Artemisinin and its synthetic derivatives as a possible therapy for cancer. Med Sci (Basel) 6: 19.

5.      Yoon MK, Mitrea DM, Ou L, Kriwacki RW (2012) Cell cycle regulation by the intrinsically disordered proteins p21 and p27. Biochem Soc Trans 40: 981-988.

6.      Olliaro PL, Haynes RK, Meunier B, Yuthavong Y (2001) Possible modes of action of the artemisinin-type compounds. Trends Parasitol 17: 122–126.

7.      Crespo-Ortiz MP, Wei MQ (2012) Antitumor activity of artemisinin and its derivatives: From a well-known antimalarial agent to a potential anticancer drug. J Biomed Biotechnol 247597.

8.      Willoughby JA, Sundar SN, Cheung M, Tin AS, Modiano J, et al. (2009) Artemisinin blocks prostate cancer growth and cell cycle progression by disrupting Sp1 interactions with the cyclin-dependent kinase-4 (CDK4) promoter and inhibiting CDK4 gene expression. J Biol Chem 284: 2203-2213.

9.      Weifeng T, Feng S, Xiangji L, Changging S, Zhiquian Q, et al. (2011) Artemisinin inhibits in vitro and in vivo invasion and metastasis of human hepatocellular carcinoma cells. Phytomedicine 18: 158–162.

10.   Nong X, Rajbanshi G, Chen L, Li J, Li Z, et al. (2019) Effect of artesunate and relation with TGF-β1 and SMAD3 signaling on experimental hypertrophic scar model in rabbit ear. Arch Dermatol Res 311: 761-772.

11.   Härtel A, Jung T, Carter SR (2018) Artemether for topical use in patients with seborrhoeic keratosis. Br J Dermatol 179: 1225-1226.

12.   Raffetin A, Bruneel F, Roussel C (2018) Use of artesunate in non-malarial indications. Med Mal Infect 48: 238-249.

13.   Efferth T, Romero MR, Wolf DG, Stamminger T, Marin JJ, et al. (2008) The antiviral activities of artemisinin and artesunate. Clin Infect Dis 47: 804-811.

14.   Uzun T, Toptas O (2020) Artesunate: Could be an alternative drug to chloroquine in COVID-19 treatment? Chin Med 15: 54.

15.   Lin Y, Wu F, Xie Z (2020) Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 32: 417-420.